Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASCEND - A Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of the Endothelin Receptor Antagonist Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 Diabetes Mellitus and Diabetic Nephropathy

NCT00120328 is registered in ClinicalTrials.gov with Speedel Pharma Ltd. as lead sponsor.

NCT NCT00120328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00120328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASCEND - A Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of the Endothelin Receptor Antagonist Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Lead sponsor
Speedel Pharma Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2005
Completion date
February 28, 2007
Enrollment
2,364
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy